Innovating Works

Basilea

A stranger
Train2Target: An integrated mulTidisciplinary appRoach towards a new generAtIon of aNtibiotics Targeting function... Basilea Pharmaceutica International AG participó en un H2020: H2020-MSCA-ITN-2016 Train2Target is a multidisciplinary European Training Network built to address the challenge of the discovery of alternative antimicrobials....
2016-08-31 - 2020-12-31 | financed
IABC PROGRAMME: iABC Programme Basilea Pharmaceutica International AG participó en un FP6: Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
2015-08-01 - 2021-12-31 | financed
COMBACTE-CARE: Combatting Bacterial Resistance in Europe - Carbapenem Resistance Basilea Pharmaceutica International AG participó en un FP6: Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!Antibiotic resistance is a global public health concern recent...
2015-03-01 - 2020-02-28 | financed
COMBACTE-MAGNET: Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections Basilea Pharmaceutica International AG participó en un FP6: Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of mult...
2015-01-01 - 2021-12-31 | financed
ENABLE: European Gram Negative Antibacterial Engine Basilea Pharmaceutica International AG participó en un FP6: The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens...
2014-02-01 - 2020-01-31 | financed
TRANSLOCATION: Molecular basis of the outer membrane permeability Basilea Pharmaceutica International AG participó en un FP6: Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and...
2013-01-01 - 2018-06-30 | financed
COMBACTE-MAGNET: Combatting Bacterial Resistance in Europe Molecules against Gram Negative Infections Basilea Pharmaceutica International AG participó en un FP7: Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of mult...
financed
COMBACTE-CARE: Combatting Bacterial Resistance in Europe Carbapenem Resistance Basilea Pharmaceutica International AG participó en un FP7: Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge! Antibiotic resistance is a global public health concern recen...
financed
IABC PROGRAMME: iABC Programme Basilea Pharmaceutica International AG participó en un FP7: Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
financed
TRANSLOCATION: Molecular basis of the outer membrane permeability Basilea Pharmaceutica International AG participó en un FP7: Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and...
financed
ENABLE: European Gram Negative Antibacterial Engine Basilea Pharmaceutica International AG participó en un FP7: The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens...
financed
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.